Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study
The Science, Technology and Economic Commission of Shanghai Pudong New Area Municipality and Shanghai Haihe Biopharma Co., Ltd.
Authors
- Fugen Li (ORCID: https://orcid.org/0000-0002-1491-7667)
- Jun Zhu (ORCID: https://orcid.org/0000-0002-0859-3483)
- Qiuying Ma
- Meiyu Fang (ORCID: https://orcid.org/0000-0001-9369-3640)
- Zhengfu Fan
- Yuqin Song (ORCID: https://orcid.org/0000-0001-5451-6481)
- Chao Lv (ORCID: https://orcid.org/0000-0002-4087-4672)
- Jilong Yang (ORCID: https://orcid.org/0000-0001-5162-3740)
- Xianan Li (ORCID: https://orcid.org/0000-0002-5872-9019)
- David Sommerhalder (ORCID: https://orcid.org/0000-0002-7033-9064)
- Han Tun
- Songda Yu
- Patrick Connor Johnson (ORCID: https://orcid.org/0000-0002-3943-6608)
- Yun Yang (ORCID: https://orcid.org/0000-0001-8478-3185)
- Dan Liu
- Jin Wang (ORCID: https://orcid.org/0000-0001-5178-7606)
- Zhiming Li (ORCID: https://orcid.org/0000-0002-5031-8362)
- Tian Gao (ORCID: https://orcid.org/0000-0002-8561-4540)
- Lin Shen (ORCID: https://orcid.org/0000-0003-2392-3353)
- Jifang Gong (ORCID: https://orcid.org/0000-0003-3798-7024)
- Javier Munozi
Institutions
- Sun Yat-sen University (CN)
- Peking University (CN)
- Texas Oncology (US)
- WinnMed (US)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Peking University Cancer Hospital (CN)
- Zhejiang Cancer Hospital (CN)
- Hunan Cancer Hospital (CN)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Mayo Clinic in Florida (US)
- Sun Yat-sen University Cancer Center (CN)
- Ministry of Education (ET)
- Hangzhou Cancer Hospital (CN)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1016/j.eclinm.2025.103398
- Citations
- 2
- Primary Topic
- Chromatin Remodeling and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.61